Adaptin Bio (APTN) Net Cash Flow (2024 - 2026)

Adaptin Bio's Net Cash Flow history runs 3 years deep, the most recent figure standing at -$157865.0 for Q1 2026.

• In Q1 2026, Net Cash Flow fell 106.75% year-over-year to -$157865.0; the TTM figure through Mar 2026 stood at -$2.1 million (down 187.5% YoY), while the FY2025 annual figure was $425089.0, up 1349.28% from the prior year.
• Net Cash Flow came in at -$157865.0 for Q1 2026 at Adaptin Bio, down from -$119915.0 in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $2.3 million in Q1 2025 to a low of -$1.0 million in Q2 2025.
• A 3-year average of $32950.6 and a median of -$81223.0 in 2024 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 767160.33% in 2025 and fell as far as 5564.07% in 2025.
• Adaptin Bio's Net Cash Flow stood at -$81223.0 in 2024, then sank by 47.64% to -$119915.0 in 2025, then slumped by 31.65% to -$157865.0 in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$157865.0, -$119915.0, and -$772430.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison